"Next Generation reference laboratory focused on proprietary, molecular biomarkers"
Grant :
NovaMedics Technology Validation Fund
Next Generation reference laboratory focused on proprietary, molecular biomarkers. PrognostiX has a robust pipeline of products in development, which targets cardiovascular disease, respiratory disease, cancer, and liver disease. The company currently has one FDA cleared diagnostic test, three products in development and eight additional targets for future product development. PrognostiX took its initial product, CardioMPO?, from the concept stage to FDA clearance in 13 months and within 18 months the product was generating revenue from direct sales. PrognostiX granted licenses for CardioMPO? to three large diagnostic companies: Biosite, Dade Behring, and Abbott Diagnostics. PrognostiX has assembled an experienced management team of seasoned professionals with experience in assay development, laboratory services, sales and marketing planning and implementation.
